Home Cart Sign in  
Chemical Structure| 220246-81-1 Chemical Structure| 220246-81-1

Structure of OR-1896
CAS No.: 220246-81-1

Chemical Structure| 220246-81-1

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

OR-1896 is an active metabolite of Levosimendan, a highly selective phosphodiesterase (PDE III) inhibitor and potent vasodilator that opens ATP-sensitive K+ channels and has calcium-sensitizing effects, alleviating cardiomyocyte apoptosis, cardiac remodeling, and myocarditis.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of OR-1896

CAS No. :220246-81-1
Formula : C13H15N3O2
M.W : 245.28
SMILES Code : CC(NC1=CC=C(C([C@H](C)C2)=NNC2=O)C=C1)=O
MDL No. :MFCD09952125

Safety of OR-1896

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319
Precautionary Statements:P501-P270-P264-P280-P302+P352-P337+P313-P305+P351+P338-P362+P364-P332+P313-P301+P312+P330

Isoform Comparison

Biological Activity

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Wistar rats Rat cremaster muscle arterioles Topical administration 1 nM – 100 μM Cumulative concentration administration OR-1896 elicited arteriolar dilation via activation of K ATP channels Pharmacol Rep. 2013;65(5):1304-10
Goto-Kakizaki (GK) rats Myocardial infarction (MI) model Oral 40 mg/kg/day Continued for 12 weeks OR-1896 improved ejection fraction and fractional shortening in GK rats with MI, ameliorated post-infarct cardiac hypertrophy, and prevented the MI-induced increase in cardiac mRNA for atrial natriuretic peptide, monocyte chemoattractant protein-1, and connective tissue growth factor, markers of pressure/volume overload, inflammation, and fibrosis, respectively. OR-1896 also suppressed mRNA for senescence-associated p16INK4A and p19ARF. The beneficial effects of OR-1896 were more prominent at week 12 than at week 4. OR-1896 did not influence systolic blood pressure, blood glucose level, myocardial infarct size, or cardiovascular mortality. Br J Pharmacol. 2010 May;160(1):142-52

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

4.08mL

0.82mL

0.41mL

20.38mL

4.08mL

2.04mL

40.77mL

8.15mL

4.08mL

 

Historical Records

Categories